Pregled bibliografske jedinice broj: 1254773
Modeling of Parkinson’s disease by intrastriatal administration of a diabetogenic compound
Modeling of Parkinson’s disease by intrastriatal administration of a diabetogenic compound // Pharmaca 2022 ; 52 Suppl 2 / Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara (ur.).
Zagreb: Hrvatsko društvo farmakologa, 2022. str. 54-54 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1254773 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Modeling of Parkinson’s disease by intrastriatal administration of a diabetogenic compound
Autori
Knezović, Ana ; Osmanović Barilar, Jelena ; Farkaš, Vladimir ; Bagarić, Robert ; Virag, Davor ; Babić Perhoč, Ana ; Homolak, Jan ; Salković- Petrišić, Melita
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Pharmaca 2022 ; 52 Suppl 2
/ Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara - Zagreb : Hrvatsko društvo farmakologa, 2022, 54-54
Skup
10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation
Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Parkinson's disease ; streptozotocin ; striatum
Sažetak
Neurodegenerative diseases (NDs) share a number of molecular and cellular pathologies and therapeutic approaches have not been too successful. Recently, metabolic dysfunction was proposed as a common fundamental threat of NDs development and type 2 diabetes as a risk factor for Parkinson’s disease (PD). Diabetes in animals is generated by peripheral administration of streptozotocin, while its intracerebroventricular administration induces insulin resistance in the brain (Alzheimer’s disease animal model). The aim of this project is to examine whether metabolic dysfunction caused by direct application of streptozotocin to brain region affected in PD (striatum) can induce symptoms characteristic of PD (motoric deficit, cognitive and behavioural alterations). Adult Male Wistar rats were given intrastriatally (is) streptozotocin (3 mg/kg ; STZis) or vehicle and one month after, cognitive, behavioural and motoric functions were tested by Rota Rod, Novel Object Recognition, Passive Avoidance, Morris Water Maze, Elevated Plus Maze and CatWalk, and glucose uptake assessed by PET scan. Data were analyzed by Kruskal-Wallis and Mann-Whitney U test. STZis rats showed deficits in motoric functions, spatial learning and memory, fear conditioned and recognition memory, and anxiety- like behaviour and additionally impaired brain glucose uptake/metabolism. The results demonstrate for the first time the development of PD hallmark symptoms after instrastriatal STZ administration, indicating its possible use to generate a new model of PD with both motor and non-motor symptoms The STZis rat model could provide a better translation value in testing of novel drugs so its further characterization is needed to elucidate the underlying mechanisms of PD pathology development.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
IP-2018-01-8938 - Mehanizmi nutrijentom posredovanih učinaka endogenog glukagonu sličnog peptida-1 na kognitivne i metaboličke poremećaje u eksperimentalnim modelima neurodegenerativnih bolesti (NutrientGLP-1) (Šalković-Petrišić, Melita, HRZZ - 2018-01) ( CroRIS)
--KK.01.1.1.01.0007 - Znanstveni centar izvrnosti - Eksperimentalna i klinička istraživanja hipoksijsko-ishemijskog oštećenja mozga u perinatalnoj i odrasloj dobi (ZCI - NEURO) (Judaš, Miloš) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Melita Šalković-Petrišić
(autor)
Robert Bagarić
(autor)
Davor Virag
(autor)
Vladimir Farkaš
(autor)
Jelena Osmanović
(autor)
Jan Homolak
(autor)
Ana Babić Perhoč
(autor)
Ana Knezović
(autor)